Servicio Andaluz de Salud.

Servicio Andaluz de Salud.

SEARCH FILTERS
Time filter
Source Type

The invention relates to the field of oncology and cancer treatment. The invention relates to methods for predicting the risk of recurrence of breast tumors using the expression signature of particular miRNAs. Specifically, the invention relates to a method for determining the risk of recurrence of breast cancer which comprises measuring the expression levels of at least one miRNA selected from the group consisting of miR-149-5p (SEQ ID NO: 1), miR-10a-5p, (SEQ ID NO: 2), miR-20b-5p, (SEQ ID NO: 3), miR-30a-3p (SEQ ID NO: 4), and miR-342-5p, (SEQ ID NO: 5) in a sample of the tumor, wherein a change in the expression level of at least one miRNA in the tumor with respect to the expression level in a control sample is indicative of a high risk of recurrence of the tumor. The invention also relates to tools and kits for carrying out the method of the invention.


Patent
Servicio Andaluz De Salud and University of Granada | Date: 2017-02-01

The invention relates to an aqueous melatonin composition exhibiting surprising long-term stability and allowing high concentrations of said water-insoluble active ingredient. The properties of said composition render it useful as an injectable, for example, for the intravenous administration thereof.


Patent
Servicio Andaluz De Salud | Date: 2017-03-08

Method of obtaining useful data for diagnosing the presence of cancer in an individual and to determine the stage or degree of progression of the cancer. Also to determine response to therapy and group subjects into responders and non-responders. Kit or device comprising the elements necessary to carry out this method and its uses.


Patent
Plus Vitech S.L. and Servicio Andaluz De Salud | Date: 2017-05-31

The present invention relates to a composition comprising a neurokinin-1 receptor antagonist and at least one excipient selected from an oil, a fatty acid or a polyol, as well as to an administration form for administering a formulation, wherein said administration form is selected from: inhalant, nebulization, vapor, smoke or aerosol and comprises said composition. In addition, the invention relates to said composition for use as medicament, said administration form for use as medicament, preferably said composition for use as medicament in the treatment of at least one disease of the respiratory tract, or said administration form for use as medicament in the treatment of at least one disease of the respiratory tract. Moreover, the invention also provides methods for producing said composition and said administration form, as well as a kit of parts comprising said composition and an administration device.


Patent
University of Granada and Servicio Andaluz De Salud | Date: 2017-06-21

The present invention relates to a serum-free conditioned medium that solves the drawbacks mentioned in the prior art, as it does not require prior handling of the cells, and it furthermore allows starting from a large population with no additional cost. This medium favors in vitro proliferation and conservation of the pluripotency potential that allows maintaining a state that is undifferentiated with respect to the subpopulation of cancer stem cells (CSCs) and in turn does not allow survival of the differentiated cells.


Patent
Servicio Andaluz De Salud and Mount Sinai School of Medicine | Date: 2017-05-10

The present invention describes the use of a group of single-nucleotide polymorphisms (SNPs) or variants in the gene NFKB1 in order to obtain data useful for the prognosis of a disease occurring with sensorineural hearing loss, and to the kit or devices and uses thereof.


Grant
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: PHC-24-2015 | Award Amount: 14.94M | Year: 2016

Pharmacogenomics is the study of genetic variability affecting an individuals response to a drug. Its use allows personalized medicine and reduction in trial and error prescribing leading to more efficacious, safer and cost-effective drug therapy. The U-PGx consortium will investigate a pre-emptive genotyping approach (that is: multiple pharmacogenomic variants are collected prospectively and embedded into the patients electronic record) of a panel of important pharmacogenomic variants as a new model of personalised medicine. To meet this goal we combine existing pharmacogenomics guidelines and novel health IT solutions. Implementation will be conducted at a large scale in seven existing European health care environments and accounts for the diversity in health system organisations and settings. Feasibility, health outcome and cost-effectiveness will be investigated. We will formulate European strategies for improving clinical implementation of pharmacogenomics based on the findings of this project.


Grant
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: PHC-18-2015 | Award Amount: 8.19M | Year: 2016

Liver cancer in the paediatric population is rare with an incidence approximately 1-1.5 per million population. The commonest tumour seen in the childhood population is hepatoblastoma (HB), usually seen in young children and infants. Much rarer (about 10% of paediatric liver cancers) is hepatocellular carcinoma (HCC), usually seen in the teenage population and sometimes associated with underlying cirrhotic liver diseases. The ChiLTERN project relates to topic PHC 18 establishing effectiveness of health care interventions in the paediatric population. The ChiLTERN project builds on a unique opportunity to undertake a comprehensive research programme linked to an ambitious global partnership which will see the single largest clinical trial (the Paediatric Hepatic International Tumour Trial - PHITT) ever undertaken in this population of patients, with several randomised questions in six subgroups of patients. ChiLTERN will allow us to move towards an era of personalised therapy in which each patient will receive the correct amount of chemotherapy and will undergo has the best surgical operation (surgical resection or liver transplant). By using both clinical and biological information, we can assign patients more accurately to risk groups based on their survival. Using genetic tests and biomarkers, we will determine those children who may be at risk of developing long term side effects (deafness, heart failure, kidney damage). In addition, biomarkers will allow us to monitor during therapy and detect toxicities early before serious damage is done so that we can adapt treatment and prevent these problems. Finally, we will be using imaging technology tools which will help our surgeons plan liver operations more safely and effectively. Ultimately ChiLTERN will allow us to cure more children with liver cancer, expose fewer children to toxic chemotherapy and ensure their surgery is both effective and safe.


Grant
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: PHC-28-2015 | Award Amount: 4.98M | Year: 2016

The main objective of POWER2DM is to develop and validate a personalized self-management support system (SMSS) for T1 and T2 diabetes patients that combines and integrates (1) a decision support system (DSS) based on leading European predictive personalized models for diabetes interlinked with predictive computer models, (2) automated e-coaching functionalities based on Behavioural Change Theories, and (3) real-time Personal Data processing and interpretation. The DSS will be based on the complementary combination of proven predictive models for short term plasma glucose prediction, medium term diabetes progression, and long term risk scoring for diabetes complications. These models will be integrated in adaptive personalized behavior change interventions to increase adherence of the patients to their care program and improve their interaction with health professionals. A cloud-based Data Integration Service, collecting and processing data from personal devices and EHR/PHR in real-time feeds the DSS. The results of the SMSS with respect to clinical parameters, awareness, acceptance and empowerment of the patient to participate in the care process will be evaluated in three studies in NL, DE and ES. The deliverables of the project will increase self-management capabilities and participation of the patient in the care process, resulting in better self-control and management of the disease. This will lead to better glucose management, thereby preventing severe episodes and long-term complications. POWER2DM will reinforce the prevention sector in healthcare by raising the acceptance of SMSS based on DSS that use predictive models fed by data from personal devices. POWER2DM will challenge individuals towards more frequent and long-term use of personal devices for self-monitoring, boosting the development of these devices. POWER2DM will thereby make an essential step forward in empowering the patient, advancing prevention and decreasing disease burden and costs.


Grant
Agency: European Commission | Branch: H2020 | Program: PCP | Phase: SC1-PM-12-2016 | Award Amount: 4.66M | Year: 2017

Patient Empowerment Individualized tackling of unnecessary stress, in particular when related to healthcare procedures, promises to enhance the autonomy and quality of life of many people and yield a significant contribution to self-empowerment, thus relieving careers and related persons from personal assistance. Not at least, also a considerable economic relief (see Impact). This is the topic the STARS consortium is determined to deal with. Of course, as will be shown, the objective is complex and ambitious and has to meet challenges from smart vital signs measuring to wireless real-time transfer of large data amounts to big data management. Nevertheless, concerning the expectable positive impact there is a large potential of revenue for the efforts. And, regarding present technological progress, it seems absolutely feasible to face this challenge when doing this inby a concerted, multidisciplinary, cross-linked effort. To achieve the aim, our proposal addresses an advanced, eHealth based concept for tailored avoidance and/or reduction of healthcare related stress, beginning as early as in the preclinical phase, proceeding during their hospitalisation until the end of the aftercare period. I.a. it can be expected that, recovery time will be shortened, harmful side-effects of sedating drugs will be prevented and costs will be reduced, which in sum will be an important contribution to a cost-effective healthcare system in the next decades.

Loading Servicio Andaluz de Salud. collaborators
Loading Servicio Andaluz de Salud. collaborators